Briacell Therapeutics Corp
BCTX10.220USD
+0.140+1.39%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
19.25MMarket Cap
LossP/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Briacell Therapeutics Corp Info
Ticker SymbolBCTX
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
CEODr. William V. Williams, M.D.
Number of employees17
Security typeOrdinary Share
Fiscal year-endOct 12
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Ticker SymbolBCTX
IPO dateOct 12, 2006
CEODr. William V. Williams, M.D.
Company Executives of Briacell Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.13K
-96.81%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
-25.81%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
163.00
+36.97%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
18.00
-99.81%
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.13K
-96.81%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
-25.81%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
163.00
+36.97%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
18.00
-99.81%
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Oct 18
Updated: Sat, Oct 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
5.31%
Iroquois Capital Management, LLC
2.97%
L5 Capital Inc.
0.92%
Lynwood Capital Management Inc.
0.57%
3I Management LLC
0.49%
Other
89.74%
Shareholders
Shareholders
Proportion
Heights Capital Management, Inc.
5.31%
Iroquois Capital Management, LLC
2.97%
L5 Capital Inc.
0.92%
Lynwood Capital Management Inc.
0.57%
3I Management LLC
0.49%
Other
89.74%
Shareholder Types
Shareholders
Proportion
Investment Advisor
5.39%
Hedge Fund
2.97%
Investment Advisor/Hedge Fund
1.26%
Corporation
0.92%
Individual Investor
0.20%
Research Firm
0.03%
Other
89.22%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
57
182.01K
9.66%
+123.64K
2025Q2
65
831.24K
7.95%
-645.60K
2025Q1
68
476.26K
7.27%
-513.92K
2024Q4
65
403.53K
10.88%
-198.25K
2024Q3
64
441.30K
30.40%
+131.88K
2024Q2
63
437.48K
31.09%
+121.43K
2024Q1
62
332.09K
21.52%
-17.16K
2023Q4
67
402.86K
34.69%
+35.57K
2023Q3
74
369.20K
35.11%
-158.11K
2023Q2
84
434.95K
41.59%
-338.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Heights Capital Management, Inc.
100.00K
5.31%
+100.00K
--
Jul 15, 2025
Iroquois Capital Management, LLC
56.00K
2.97%
+56.00K
--
Jul 21, 2025
L5 Capital Inc.
17.40K
0.92%
+450.00
+2.65%
Dec 10, 2024
Lynwood Capital Management Inc.
10.65K
0.57%
+114.00
+1.08%
Mar 31, 2024
3I Management LLC
9.17K
0.49%
-27.73K
-75.15%
Mar 31, 2025
Sabby Management, LLC
3.95K
0.21%
+3.95K
--
Jun 30, 2025
UBS Financial Services, Inc.
1.52K
0.08%
-383.00
-20.08%
Jun 30, 2025
Williams (William V)
35.30K
1.87%
+28.26K
+401.29%
Aug 01, 2025
Bondarenko (Jamieson)
1.08K
0.06%
+278.00
+34.79%
Dec 09, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Date
Type
Ratio
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
